X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (92) 92
index medicus (84) 84
female (82) 82
middle aged (82) 82
oncology (82) 82
male (77) 77
aged (73) 73
adult (70) 70
aged, 80 and over (45) 45
treatment outcome (44) 44
neoplasms - drug therapy (40) 40
article (39) 39
cancer (38) 38
solid tumors (37) 37
antineoplastic combined chemotherapy protocols - therapeutic use (35) 35
mutation (33) 33
young adult (33) 33
clinical trials (32) 32
antineoplastic combined chemotherapy protocols - adverse effects (27) 27
bevacizumab (24) 24
patients (24) 24
tumors (24) 24
adolescent (22) 22
medicine & public health (21) 21
neoplasms - genetics (21) 21
disease-free survival (20) 20
pharmacology/toxicology (20) 20
research (20) 20
antineoplastic agents - therapeutic use (19) 19
care and treatment (19) 19
pharmacology & pharmacy (19) 19
maximum tolerated dose (17) 17
neoplasms - pathology (17) 17
chemotherapy (16) 16
retrospective studies (16) 16
kaplan-meier estimate (15) 15
protein kinase inhibitors - therapeutic use (15) 15
breast-cancer (14) 14
expression (14) 14
metastasis (14) 14
phosphatidylinositol 3-kinases - genetics (14) 14
therapy (14) 14
tor serine-threonine kinases - antagonists & inhibitors (14) 14
antineoplastic combined chemotherapy protocols - administration & dosage (13) 13
complications and side effects (13) 13
drug therapy (13) 13
immunotherapy (13) 13
neoplasms (13) 13
resistance (13) 13
sirolimus - administration & dosage (13) 13
sirolimus - analogs & derivatives (13) 13
melanoma (12) 12
mutations (12) 12
neoplasm staging (12) 12
phase i trial (12) 12
research paper (12) 12
studies (12) 12
survival (12) 12
angiogenesis (11) 11
antibodies, monoclonal, humanized - administration & dosage (11) 11
cell lung-cancer (11) 11
class i phosphatidylinositol 3-kinases (11) 11
dosage and administration (11) 11
lung-cancer (11) 11
neoplasms - mortality (11) 11
prognosis (11) 11
toxicity (11) 11
cancer therapies (10) 10
cell biology (10) 10
inhibition (10) 10
proto-oncogene proteins b-raf - genetics (10) 10
renal-cell carcinoma (10) 10
targeted therapy (10) 10
temsirolimus (10) 10
cancer research (9) 9
colorectal-cancer (9) 9
dose-response relationship, drug (9) 9
medical research (9) 9
phase i (9) 9
safety (9) 9
antibodies, monoclonal, humanized - adverse effects (8) 8
cancer patients (8) 8
colorectal cancer (8) 8
genetic aspects (8) 8
liver neoplasms - secondary (8) 8
neoplasm metastasis (8) 8
open-label (8) 8
pembrolizumab (8) 8
protein kinase inhibitors - administration & dosage (8) 8
survival rate (8) 8
analysis (7) 7
antimitotic agents (7) 7
antineoplastic agents (7) 7
antineoplastic agents - adverse effects (7) 7
biomarkers (7) 7
biomarkers, tumor - genetics (7) 7
breast cancer (7) 7
child (7) 7
clinical trials, phase i as topic (7) 7
combination (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 11/2018, Volume 82, Issue 5, pp. 877 - 885
We investigated hepatic arterial infusion (HAI) oxaliplatin combined with capecitabine +/− bevacizumab in advanced cancer with predominant liver... 
Hepatic arterial infusion | Oxaliplatin | Medicine & Public Health | Capecitabine | Oncology | Cancer Research | Maximum tolerated dose | Pharmacology/Toxicology | Dose-limiting toxicity | Bevacizumab | SURVIVAL | EFFICACY | COMBINATION | METASTATIC COLORECTAL-CANCER | CHEMOTHERAPY | PACLITAXEL | BREAST-CANCER | THERAPY | ONCOLOGY | DISEASE | PHARMACOLOGY & PHARMACY | CARCINOMA | Capecitabine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Bevacizumab - administration & dosage | Administration, Oral | Neoplasm Invasiveness | Bevacizumab - adverse effects | Humans | Middle Aged | Hepatic Artery | Liver Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Treatment Outcome | Oxaliplatin - adverse effects | Maximum Tolerated Dose | Capecitabine - adverse effects | Female | Oxaliplatin - administration & dosage | Liver Neoplasms - secondary | Infusions, Intra-Arterial | Antimitotic agents | Liver cancer | Cancer patients | Liver | Therapeutics | Clinical trials | Product development | Antineoplastic agents | Homeopathy | Materia medica and therapeutics | Biliary tract | Thrombocytopenia | Intravenous administration | Anemia | Toxicity | Diarrhea | Nausea | Patients | Infusion | Vomiting | Pancreas | Hypomagnesemia | Cancer | Neutropenia
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 6, pp. 672 - 673
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 08/2017, Volume 127, Issue 8, pp. 2930 - 2940
Programmed death-1-directed (PD-1-directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies... 
CELL LUNG-CANCER | MEDICINE, RESEARCH & EXPERIMENTAL | MELANOMA | PEMBROLIZUMAB | LIGANDS | IMMUNOTHERAPY | SAFETY | TOLERANCE | ADAPTIVE IMMUNE RESISTANCE | EXPRESSION | Immunohistochemistry | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Humans | Gene Expression Regulation, Neoplastic | Tumor Microenvironment | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Interferon-gamma - metabolism | Immune System | Carcinoma - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Signal Transduction | Skin Neoplasms - immunology | Carcinoma - immunology | Programmed Cell Death 1 Receptor - metabolism | Treatment Outcome | Stomach Neoplasms - drug therapy | Stomach Neoplasms - immunology | Carcinoma, Non-Small-Cell Lung - immunology | B7-H1 Antigen - metabolism | Lung Neoplasms - immunology | Pilot Projects | Sequence Analysis, RNA | Biopsy | Melanoma - immunology | Melanoma - drug therapy | ROC Curve | Carcinoma, Non-Small-Cell Lung - drug therapy | PD-1 protein | Lung cancer | Clinical trials | Cytotoxicity | Biology | Lymphocytes T | Cancer therapies | Metastases | Lymphocytes | Neck | Adaptation | Antigen presentation | Squamous cell carcinoma | Cytokines | Melanoma | Inflammation | Gene expression | Immune checkpoint | PD-L1 protein | Head and neck cancer | Antitumor activity | Ligands | Interferon | Chemokines | Apoptosis | Tumors
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2018, Volume 36, Issue 1, pp. 61 - 67
Purpose The anti-programmed death-1 antibody pembrolizumab was evaluated in KEYNOTE-028, a multicohort, phase IB study of patients with programmed death... 
LIGAND-1 | MULTICENTER | ONCOLOGY | PATHWAY | SQUAMOUS-CELL CARCINOMA | OPEN-LABEL | PD-1 | EXPRESSION | CANCER | CD8(+) T-CELLS
Journal Article
Nature, ISSN 0028-0836, 02/2018, Volume 554, Issue 7691, pp. 189 - 194
Journal Article
Journal Article
Journal of Clinical and Aesthetic Dermatology, ISSN 1941-2789, 09/2012, Volume 5, Issue 9, pp. 27 - 36
Salivary duct carcinoma is an infrequent and highly aggressive cancer that rarely metastasizes to the skin. Inflammatory cutaneous metastatic carcinoma is... 
Journal Article
Journal Article
The Journal of Clinical and Aesthetic Dermatology, ISSN 1941-2789, 9/2012, Volume 5, Issue 9, pp. 27 - 36
Background : Salivary duct carcinoma is an infrequent and highly aggressive cancer that rarely metastasizes to the skin. Inflammatory cutaneous metastatic... 
Literature Review and Case Report
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 07/2015, Volume 107, Issue 7
Journal Article